Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Non-small cell lung cancer (NSCLC) therapy has entered a rapidly advancing era of precision medicine with an ever increasing number of drugs directed against a variety of specific tumor targets. Amongst these new agents, tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) are most frequently used. However, as only a sensitive subgroup of patients benefits from targeting drugs, predictive biomarkers are needed. Positron emission tomography (PET) may offer such a biomarker for predicting therapy efficacy. Some of the TKIs and mAbs that are in clinical use can be radioactively labeled and used as tracers. PET can visualize and quantify tumor specific uptake of radiolabeled targeting drugs, allowing for characterization of their pharmacokinetic behavior. In this review, the clinical potential of PET using radiolabeled TKIs (TKI-PET) and mAbs (immuno-PET) in NSCLC is discussed, and an overview is provided of the most relevant preclinical and clinical studies.

Original languageEnglish
Pages (from-to)1-13
Number of pages13
JournalLung Cancer
Volume107
DOIs
Publication statusPublished - 1 May 2017

Cite this

@article{272708e2b5074b908518cbb1a43255c1,
title = "Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET",
abstract = "Non-small cell lung cancer (NSCLC) therapy has entered a rapidly advancing era of precision medicine with an ever increasing number of drugs directed against a variety of specific tumor targets. Amongst these new agents, tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) are most frequently used. However, as only a sensitive subgroup of patients benefits from targeting drugs, predictive biomarkers are needed. Positron emission tomography (PET) may offer such a biomarker for predicting therapy efficacy. Some of the TKIs and mAbs that are in clinical use can be radioactively labeled and used as tracers. PET can visualize and quantify tumor specific uptake of radiolabeled targeting drugs, allowing for characterization of their pharmacokinetic behavior. In this review, the clinical potential of PET using radiolabeled TKIs (TKI-PET) and mAbs (immuno-PET) in NSCLC is discussed, and an overview is provided of the most relevant preclinical and clinical studies.",
keywords = "immuno-PET, NSCLC, PET, TKI-PET",
author = "I. Bahce and M. Yaqub and Smit, {E. F.} and Lammertsma, {A. A.} and {van Dongen}, {G. A.M.S.} and Hendrikse, {N. H.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.lungcan.2016.05.025",
language = "English",
volume = "107",
pages = "1--13",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET

AU - Bahce, I.

AU - Yaqub, M.

AU - Smit, E. F.

AU - Lammertsma, A. A.

AU - van Dongen, G. A.M.S.

AU - Hendrikse, N. H.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Non-small cell lung cancer (NSCLC) therapy has entered a rapidly advancing era of precision medicine with an ever increasing number of drugs directed against a variety of specific tumor targets. Amongst these new agents, tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) are most frequently used. However, as only a sensitive subgroup of patients benefits from targeting drugs, predictive biomarkers are needed. Positron emission tomography (PET) may offer such a biomarker for predicting therapy efficacy. Some of the TKIs and mAbs that are in clinical use can be radioactively labeled and used as tracers. PET can visualize and quantify tumor specific uptake of radiolabeled targeting drugs, allowing for characterization of their pharmacokinetic behavior. In this review, the clinical potential of PET using radiolabeled TKIs (TKI-PET) and mAbs (immuno-PET) in NSCLC is discussed, and an overview is provided of the most relevant preclinical and clinical studies.

AB - Non-small cell lung cancer (NSCLC) therapy has entered a rapidly advancing era of precision medicine with an ever increasing number of drugs directed against a variety of specific tumor targets. Amongst these new agents, tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) are most frequently used. However, as only a sensitive subgroup of patients benefits from targeting drugs, predictive biomarkers are needed. Positron emission tomography (PET) may offer such a biomarker for predicting therapy efficacy. Some of the TKIs and mAbs that are in clinical use can be radioactively labeled and used as tracers. PET can visualize and quantify tumor specific uptake of radiolabeled targeting drugs, allowing for characterization of their pharmacokinetic behavior. In this review, the clinical potential of PET using radiolabeled TKIs (TKI-PET) and mAbs (immuno-PET) in NSCLC is discussed, and an overview is provided of the most relevant preclinical and clinical studies.

KW - immuno-PET

KW - NSCLC

KW - PET

KW - TKI-PET

UR - http://www.scopus.com/inward/record.url?scp=85008194201&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2016.05.025

DO - 10.1016/j.lungcan.2016.05.025

M3 - Article

VL - 107

SP - 1

EP - 13

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -